Medtronic Advances RDN with New Catheter, Multi-Organ Study, and Project Galileo
Jul 17,2025
Medtronic is making notable progress in its renal denervation (RDN) program, aiming to improve hypertension treatment through innovation in catheter design and procedural technique.
Project Pulsar has led to a next-gen Symplicity Spyral catheter designed for transradial (wrist-based) access, offering better patient outcomes and fewer complications compared to femoral access. The catheter maintains strong performance across deliverability and ease of use.
Simultaneously, Project Gemini explores multi-organ denervation, targeting both renal and hepatic arteries. Early clinical results suggest that adding hepatic denervation enhances blood pressure reduction by suppressing sympathetic nerve activity more effectively. The energy delivery algorithm has been adjusted to suit hepatic artery anatomy, and initial human trials have begun.
Looking ahead, Project Galileo—based in Ireland—aims to provide real-time intraprocedural feedback. Inspired by cardiac mapping in atrial fibrillation treatment, the goal is to verify nerve ablation success during the procedure, potentially using the same catheter with a modified energy level.
These innovations could expand RDN applications beyond hypertension, with potential cardiometabolic benefits in the future. As Medtronic sharpens its focus post-diabetes business separation, RDN is positioned as a key growth driver in its cardiovascular portfolio.
Jul 17,2025
Category：
In The News
Related Information
Videos
Watch the video，Learn more about our products and services.Diagsensor is dedicated to the research and development of ultra-micro sensors for vital signs monitoring
Learn MoreSocial Media
Our Social Media Channels Keep You Informed.
No data